Expression of p14 ARF, p15 INK4b, p16 INK4a and skp2 increases during esophageal squamous cell cancer progression

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 1026-1032

  Bai, Peng ^a   Xiao, Xue ^a   Zou, Juan ^a   Cui, Lin ^a   Bui Nguyen, Tri M ^c   Liu, Jinsong ^b   Xiao, Jianguo ^b   Chang, Bin ^d   Wu, Jin ^a   Wang, He ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d SHIHEZI UNIVERSITY   (China)

Author keywords

Apoptosis; Carcinogenesis; Esophageal squamous cell carcinoma; Senescence

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PROTEIN BCL 2; S PHASE KINASE ASSOCIATED PROTEIN 2;

ADULT; AGED; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84859638569     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.523     Document Type: Article

References (48)

1. Pisani P, Parkin DM and Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55: 891-903, 1993.
2. Sarbia M, Verreet P, Bittinger F, Dutkowski P, Heep H, Willers R and Gabbert HE: Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis. Cancer 79: 1871-1878, 1997.
3. Hu J, Li R, Sun L and Ni Y: Influence of esophageal carcinoma operations on gastroesophageal reflux. Ann Thorac Surg 78: 298-302, 2004.
4. Shan W, Yang G and Liu J: The inflammatory network: bridging senescent stroma and epithelial tumorigenesis. Front Biosci 14: 4044-4057, 2009.
5. Stein GH and Dulic V: Origins of G1 arrest in senescent human fibroblasts. Bioessays 17: 537-543, 1995.
6. Hayflick L: Theories of biological aging. Exp Gerontol 20: 145-159, 1985.
7. Oller AR, Rastogi P, Morgenthaler S and Thilly WG: A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation ssay. Mutat Res 216: 149-161, 1989.
8. Jackson AL and Loeb LA: The mutation rate and cancer. Genetics148: 1483-1490, 1998.
9. Bissell MJ and Labarge MA: Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment. Cancer Cell 7: 17-23, 2005.
10. Rosu-Myles M and Wolff L: p15Ink4b: dual function in myelopoiesis and inactivation in myeloid disease. Blood Cells Mol Dis40: 406-409, 2008.
11. Zhang Z, Rosen DG, Yao JL, Huang J and Liu J: Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod Pathol 19: 1339-1343, 2006.
12. Zindy F, Quelle DE, Roussel MF and Sherr CJ: Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203-211, 1997.
13. Shapiro GI, Edwards CD, Ewen ME and Rollins BJ: p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18: 378-387, 1998.
14. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L and Kamb A: Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 11: 987-991, 1995.
15. Fukai K, Yokosuka O, Imazeki F, Tada M, Mikata R, Miyazaki M, Ochiai T and Saisho H: Methylation status of p14ARF, p15INK4b, and p16INK4a genes in human hepatocellular carcinoma. Liver Int 25: 1209-1216, 2005.
16. Collado M, Blasco MA and Serrano M: Cellular senescence in cancer and aging. Cell 130: 223-233, 2007.
17. Rinehart CA and Torti VR: Aging and cancer: the role of stromal interactions with epithelial cells. Mol Carcinog 18: 187-192, 1997.
18. Beck JC, Hosick HL and Watkins BA: Growth of epithelium from a preneoplastic mammary outgrowth in response to mammary adipose tissue. In Vitro Cell Dev Biol 25: 409-418, 1989.
19. Hayashi N and Cunha GR: Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res 51: 4924-4930, 1991.
20. Li TY, Xu LY, Wu ZY, Liao LD, Shen JH, Xu XE, Du ZP, Zhao Q and Li EM: Reduced nuclear and ectopic cytoplasmic expression of lysyl oxidase-like 2 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Hum Pathol Dec 26, 2011 (Epub ahead of print).
21. Yang GZ, Li L, Ding HY and Zhou JS: Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: an immunohistochemical study. Exp Mol Pathol 79: 214-218, 2005.
22. Grace VM, Shalini JV, lekha TT, Devaraj SN and Devaraj H: Co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol Oncol91: 51-58, 2003.
23. DePinho RA: The age of cancer. Nature 408: 248-254, 2000.
24. Zheng WQ, Zheng JM, Ma R, Meng FF and Ni CR: Relationship between levels of Skp2 and P27 in breast carcinomas and possible role of Skp2 as targeted therapy. Steroids 70: 770-774, 2005.
25. Gil J and Peters G: Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol7: 667-677, 2006.
26. Kim WY and Sharpless NE: The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275, 2006.
27. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, etal: Tumour biology: senescence in premalignant tumours. Nature 436: 642, 2005.
28. Jin M, Piao Z, Kim NG, Park C, Shin EC, Park JH, Jung HJ, Kim CG and Kim H: p16 is a major inactivation target in hepatocellular carcinoma. Cancer 89: 60-68, 2000.
29. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA and Stratton MR: COSMIC 2005. Br J Cancer 94: 318-322, 2006.
30. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
31. Sano T, Masuda N, Oyama T and Nakajima T: Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int 52: 375-383, 2002.
32. Li TY, Xu LY, Wu ZY, Liao LD, Shen JH, Xu XE, Du ZP, Zhao Q and Li EM: Reduced nuclear and ectopic cytoplasmic expression of lysyl oxidase-like 2 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Hum Pathol: Dec 26, 2011 (Epub ahead of print).
33. Meng RD, McDonald ER 3rd, Sheikh MS, Fornace AJ Jr and El-Deiry WS: The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 1: 130-144, 2000.
34. Schwarze SR, Shi Y, Fu VX, Watson PA and Jarrard DF: Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20: 8184-8192, 2001.
35. Roberson RS, Kussick SJ, Vallieres E, Chen SY and Wu DY: Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 65: 2795-2803, 2005.
36. Wang Z, Gao D, Fukushima H, Inuzuka H, Liu P, Wan L, Sarkar FH and Wei W: Skp2: A novel potential therapeutic target for prostate cancer. Biochim Biophys Acta 1825: 11-7, 2012.
37. Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789, 2005.
38. Dowen SE, Scott A, Mukherjee G and Stanley MA: Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int J Cancer 105: 326-330, 2003.
39. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
40. Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1: 199-206, 1990.
41. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873, 1991.
42. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
43. Singh BB, Chandler FW Jr, Whitaker SB and Forbes-Nelson AE: Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85: 692-698, 1998.
44. Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
45. Ecker K and Hengst L: Skp2: caught in the Akt. Nat Cell Biol 11: 377-379, 2009.
46. Guillouf C, Grana X, Selvakumaran M, De Luca A, Giordano A, Hoffman B and Liebermann DA: Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest. Blood 85: 2691-2698, 1995.
47. Bishop JM: Cancer: the rise of the genetic paradigm. Genes Dev9: 1309-1315, 1995.
48. Campisi J: Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbours. Cell 120: 513-522, 2005.